

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-19 (Cancelled)

Claim 20 (New): An isolated peptide selected from the group consisting of GLPPDVQRV (SEQ ID NO: 1), LGLPPDVQRV (SEQ ID NO: 2), LPPDVQRV (SEQ ID NO: 3) and GLPPDVQR (SEQ ID NO: 4).

Claim 21 (New): The isolated peptide of claim 20 that is GLPPDVQRV (SEQ ID NO: 1).

Claim 22 (New): The isolated peptide of claim 20 that is LGLPPDVQRV (SEQ ID NO: 2).

Claim 23 (New): The isolated peptide of claim 20 that is LPPDVQRV (SEQ ID NO: 3).

Claim 24 (New): The isolated peptide of claim 20 that is GLPPDVQR (SEQ ID NO: 4).

Claim 25 (New): A chimeric polypeptide comprising more than one copy of the isolated peptide of claim 20.

Claim 26 (New): A composition comprising the isolated peptide of claim 20 in combination with an adjuvant.

Claim 27 (New): A composition comprising the isolated peptide of claim 20 in combination with an antigen presenting cell that expresses MHC Class I.

Claim 28 (New): The composition of claim 27, wherein said antigen presenting cell is a dendritic cell.

Claim 29 (New): A method for inducing a T cell response comprising contacting a T cell with an antigen presenting cell expressing MHC Class I with the isolated peptide of claim 20.

Claim 30 (New): The method of claim 29, wherein said antigen presenting cell expresses HLA-A2 or HLA-A*0201.

Claim 31 (New): The method of claim 30, wherein said T cell is autologous to the cell expressing HLA-A2 or HLA-A*0201.

Claim 32 (New): A method for treating melanoma comprising:
administering to a subject having melanoma at least one isolated peptide of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 as described by claim 20.

Claim 33 (New): The method of claim 32, wherein said subject expresses HLA-A2 or HLA-A*0201 and said melanoma expresses MMP-2 that comprises the amino acid sequence of the at least one peptide that is administered.

Claim 34 (New): A method for treating melanoma, comprising:
administering to a subject having melanoma an antigen presenting cell that has been contacted with at least one of the isolated peptides of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 described by claim 20;
wherein said melanoma expresses an MMP-2 polypeptide that comprises the amino acid sequence of at least one of the isolated peptides.

Claim 35 (New): The method of claim 34, wherein said subject expresses HLA-A2 or HLA-A*0201 and the antigen presenting cell is autologous to said subject.

Claim 36 (New): A method for treating melanoma, comprising:
administering to a subject having melanoma a T cell that has been activated by contacting it with an antigen presenting cell expressing HLA-A2 or HLA-A*0201 in combination with at least one of the isolated peptides of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 described by claim 20.

Claim 37 (New): The method of claim 36, wherein said T cell is autologous to said subject.

Claim 38 (New): The method of claim 37, wherein said autologous T cell is taken from the melanoma patient, multiplied *in vitro*, and reintroduced into said melanoma patient.

Claim 39 (New): An antigen presenting that has been transfected with a polynucleotide expressing an MMP-2 polypeptide comprising at least one of the sequences of SEQ ID NO: 1, 2 or 3, wherein said antigen presenting cell expresses HLA-A2 or HLA-A2*0201.